BRISBANE, Calif., June 26 /PRNewswire-FirstCall/ -- WHAT: VaxGen, Inc. Senior Vice President, Research and Development & Chief Scientific Officer, Kathrin U. Jansen, Ph.D., will give a presentation titled “Development of a Recombinant Anthrax (rPA) Vaccine” at the Engineering Conferences International Vaccine Technology Meeting. WHEN/WHERE: Wednesday, June 28, 2006, 5 p.m. Central Daylight Savings Time/Casa Magna Marriott Puerto Vallarta Resort, Puerto Vallarta About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox. The company has been awarded an $877.5 million U.S. government contract to provide 75 million doses of its recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and is a shareholder in Celltrion, Inc., a South Korean joint venture established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company’s web site at: http://www.vaxgen.com .
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comVaxGen, Inc.
CONTACT: Cynthia Kelly for VaxGen, Inc., +1-650-624-1041
Web site: http://www.vaxgen.com/
